Novel Mutations in K13 Propeller Gene of Artemisinin-Resistant Plasmodium falciparum by Isozumi Rie et al.
DISPATCHES
Rie Isozumi, Haruki Uemura, Isao Kimata,  
Yoshio Ichinose, John Logedi,  
Ahmeddin H. Omar, Akira Kaneko
We	 looked	 for	 mutations	 in	 the	 Plasmodium falciparum 
K13	 propeller	 gene	 of	 an	 artemisinin-resistant	 parasite	





The worldwide spread of malaria parasites with resis-tance to antimalarial drugs has been a serious concern 
over the past few decades. During the 2000s, Plasmodi-
um falciparum parasites acquired resistance to key drugs, 
such as chloroquine and sulfadoxine–pyrimethamine, in 
many malaria-endemic countries, including Kenya (1). 
Artemisinin-based combination therapy (ACT) has been 
introduced in most malaria-endemic countries and is the 
first-line therapy. However, the first clinical cases of arte-
misinin resistance in western Cambodia were reported in 
2008 (2), and P. falciparum with reduced in vivo suscep-
tibility to artesunate in western Cambodia was reported in 
2009 (3,4). On the basis of these findings, genome-wide 
analyses of artemisinin-resistant P. falciparum isolates 
found strong correlations between a mutant allele in the 
K13 propeller, in vitro parasite survival rates, and in vivo 
parasite clearance rates; these correlations indicate that 
mutations in the K13 propeller (especially C580Y, R539T, 
and Y439H) are important determinants of artemisinin re-
sistance (5,6). Analysis of parasites from several Cambo-
dian provinces indicated that K13 propeller mutations are 
rarely observed in samples from provinces without docu-
mented resistance but are prevalent in provinces with re-
ported resistance (6,7).
In Kenya, ACT was introduced as first-line therapy 
for P. falciparum malaria in 2004 (1). However, various 
types of antimalarial drugs—including chroloquine, sul-
fadoxine–pyrimethamine, and artemether/lumefantrine—
are available for purchase at pharmacies without physi-
cians’ prescriptions. In this study, we describe some K13 
propeller mutations of P. falciparum parasites from west-
ern Kenya.
The Study
The research was conducted at 4 islands on Lake Victo-
ria (Kibuogi, Ngodhe, Takawiri, Mfangano) and 1 shore-
line community of Mbita District (Ungoye) in western 
Kenya (Figure). In this area, the PfPR2–10 (community 
P. falciparum parasite rate standardized to the 2- to 10-
year age group) was reported in 2009 to be >40% (8). 
Although in some area of Kenya malaria has decreased, 
its prevalence remains high in the Lake Victoria basin be-
cause of the lake environment (8–10). In 2009, a total of 
50%–70% of households owned insecticide-treated bed 
nets (11), which substantially reduce the risk for trans-
mission of malaria parasites by providing barriers against 
mosquitoes. Although malaria is annually more preva-
lent in the 2 wet seasons (March–June and October– 
November) (9), in the study sites, it is highly endemic 
throughout the year.
Filter paper blood spots were collected from participants 
(online Technical Appendix Table 1, http://wwwnc.cdc.gov/
EID/article/21/3/14-0898-Techapp1.pdf) during population-
wide cross-sectional malaria surveys conducted in February 
and August 2012 and August 2013 at the 5 study sites. We 
obtained ethics approval from the Kenyatta National Hospi-
tal and the University of Nairobi. All study participants pro-
vided informed consent.
Parasitic DNA was extracted from the filter paper (12), 
and P. falciparum DNA was detected by a mitochondrial 
DNA-based PCR (13). Sequencing of the K13 propel-
ler gene was attempted on the diagnostic PCR-positive 
specimens (online Technical Appendix). The prevalence 
of P. falciparum, as determined by PCR, in the rainy and 
dry seasons was 7.2%–26.2% and 6.5%–15.5% on the 3 
small islands (Kibuogi, Ngodhe, and Takawiri), 47.3% and 
31.4% on Mfangano Island, and 38.4% and 41.9%–64.0% 
in Ungoye, respectively (Table 1).
We successfully analyzed 539 samples for the K13 
propeller gene. Nine new types of point mutations were 
identified among these samples (Table 2). Participants in-
fected with parasites harboring a mutation on the K13 pro-
peller gene are listed in online Technical Appendix Table 
2. The sequences reported in this study have been deposited 
in the DDBJ/EMBL/GenBank databases (accession nos.
AB936059–AB936067).
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We detected 4 novel nonsynonymous and 5 novel syn-
onymous mutations in the highly conserved K13 propeller 
gene of P. falciparum parasites from western Kenya. Ariey 
et al. noted that the frequency of mutant alleles strongly 
correlated with the prevalence of day 3 positivity after ACT 
treatment in humans in Cambodia and that those mutations 
reflected positive selection (6). That study found 17 mutant 
alleles in the K13 propeller gene. Among them, C580Y, 
R539T, and Y493H were prevalent and strongly related 
to in vivo delayed parasite clearance. In our study, all the 
mutations found differed from those reported in Cambodia, 
and mutant alleles were not always observed in the pro-
ceeding seasons, so some mutations could be occasionally 
introduced. Most of those mutations are not suitable for the 
life cycle of parasites, and only a few suitable for survival 
under the conditions of artemisinin selection pressure could 
be selected.
We observed no identical mutations at >2 of these 
5 study sites. Furthermore, only 1 type of mutation, A578S 
from Mfangano Island, was detected during 2 seasons, 
whereas other mutations were not observed in the next 
season, half a year later. Any family relations were not 
identified among the 4 participants harboring A578S muta-
tion in February 2012 at Mfangano Island. Point mutations 
can occasionally occur on the P. falciparum K13 propel-
ler gene as a standing variation, but most of the isolates 
that recently acquired the mutation may disappear because 
of some fitness disadvantage or the effect of a random ge-
netic drift (14).
Malaria parasites grow and multiply at 2 different bio-
logic stages in humans and mosquitoes. Therefore, isolates 
with new mutations must adapt to both circumstances. We 
detected the mutant allele A578S in the K13 propeller gene 
in 2 consecutive seasons on Mfangano Island. This muta-
tion, which modifies amino acids from being hydrophobic 
to hydrophilic, is close to the prevalent single nucleotide 
polymorphism C580Y from Cambodia that is thought to 
be necessary in protein–protein interactions, which could 
affect artemisinin susceptibility. The genotype analyses of 
the parasites from this island are critical to understanding 
the role of this mutation and ACT efficiency in this geo-
graphic area.
Our K13 propeller sequence analysis of P. falciparum 
parasites from a malaria-endemic area in Kenya did not 
detect the predicted artemisinin-resistant genotypes, but 
we observed some temporal substitutions. A limitation 
of our study was that the sample size was insufficient to 
specifically provide an understanding of this result. The 






Table 1. Prevalence	of	Plasmodium falciparum and	analysis	of	
K13	propeller	gene,	Mbita	District,	Kenya,	2012–2013 









2012	Feb Kibuogi 130 34	(26.2) 21 
Ngodhe 250 18 (7.2) 5 
Takawiri 250 34	(13.6) 19 
Mfangano 427 202	(47.3) 138 
Ungoye 250 96	(38.4) 69 
2012	Aug Kibuogi 195 17	(8.7) 10 
Ngodhe 232 36	(15.5) 18 
Takawiri 230 15	(6.5) 9 
Mfangano 706 222	(31.4) 145 
Ungoye 248 104	(41.9) 65 
2013	Aug Ungoye 250 160	(64) 40 
*PCR	detected	Plasmodium falciparum only. 
 
 





2012	Feb 2012	Aug 2013	Aug 
Nonsynonymous M442V ATG	GTG  Mfangano	(1)  
N554S AAT AGT Ungoye	(1)   
A569S GCA	TCA   Ungoye	(1) 
A578S GCT	TCT Mfangano	(4) Mfangano	(1)  
Synonymous C439C TGCTGT Ungoye	(2)   
S477S TCT	TCG Takawiri	(1)   
Y500Y TATTAC  Mfangano	(1)  
N531N AAT AAC   Ungoye	(1) 
G538G GGTGGA Mfangano	(3)   
 
DISPATCHES
malaria-endemic areas will increase our understanding of 
the relationship between the K13 propeller gene and ar-
temisinin resistance. Monitoring these molecular markers 
and the efficacy of antimalarial drugs is critical for increas-
ing understanding of artemisinin resistance and predicting 
its spread. This study identified clues that are essential in 
understanding artemisinin-resistant parasites.
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